Oncolytics Biotech Inc. (NASDAQ:ONCY) Q2 2020 Earnings Conference Call August 4, 2020 4:30 PM ET Company Participants Tom Galassi - Investor Relations Matt Coffey - President & Chief Executive Officer Andrew de Guttadauro - Global Head of Business Development Kirk Look – Chief Financial Officer Conference Call Participants Jonathan Aschoff - Roth Capital Partners John Newman - Canaccord Operator Good day, everyone and welcome to the Oncolytics Biotech Second Quarter 2020 Earnings Conference Call. Today's co ...

| --- | --- | --- | --- | |----------------------------------|----------|-------|-------| | | | | | | | | | | | | | | | | Investor Presentation March 2020 | | | | | oncolyticsbiotech.com | TSX ONC | | | Forward-Looking Statements This presentation contains certain forward-looking statements relating to the company's business prospects and the development and commercialization of pelareorep, a first-in-class systemically administered immuno-oncology agent for solid tumors and heme malignancies. These stateme ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F | o | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 | | --- | --- | | | OR | | x | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For fiscal year ended | | | December 31, 2019 | | | OR | | o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For the transition period from ____ to ____ | | | ...

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2019 Earnings Conference Call March 5, 2020 5:30 PM ET Company Participants Michael Moore – Vice President-Investor Relations and Corporate Communications Matt Coffey – President and Chief Executive Officer Kirk Look – Chief Financial Officer Andrew de Guttadauro – Global Head-Business Development Conference Call Participants Wangzhi Li – Ladenburg John Newman – Canaccord Jonathan Aschoff – Roth Capital Partners Operator Good afternoon. My name is Mike, and I’ll be y ...

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2019 Earnings Conference Call November 12, 2019 5:00 PM ET Company Participants Michael Moore - VP of IR & Corporate Communications Dr. Matt Coffey - President, CEO Kirk Look - CFO Andrew de Guttadauro - Global Head of Business Development Conference Call Participants John Newman - Canaccord Wangzhi Li - Ladenburg Jerry Isaacson - Roth Capital Operator Good day, ladies and gentlemen. My name is Kat and IÂ'll be your conference operator today. At this time, I would li ...

| --- | --- | |--------------------------------------------------|-------| | | | | | | | Investor Presentation June 2019 | | | oncolyticsbiotech.com Nasdaq ONCY TSX ONC | | Forward Looking Statements This presentation contains certain forward looking statements relating to the company's business prospects and the development and commercialization of pelareorep, a first-in-class systemically administered immuno-oncology agent for solid tumors and heme malignancies. These statements are based on management's ...

Oncolytics Biotech, Inc. (NASDAQ:ONCY) Oncolytics Co-Development Agreement Call June 5, 2019 8:30 AM ET Company Participants Michael Moore – Vice President-Investor Relations and Corporate Communications Matt Coffey – President and Chief Executive Officer Andrew de Guttadauro – President-Oncolytics Biotech U.S. and Global Head of Business Development Kirk Look – Chief Financial Officer Conference Call Participants John Newman – Canaccord Genuity Wangzhi Li – Ladenburg Thalmann Tom Shrader – BTIG Chad Messer ...

| --- | --- | |---------------------------------------------|-------| | | | | | | | Investor Presentation April 2019 | | | oncolyticsbiotech.com Nasdaq ONCY TSX | | Forward Looking Statements This presentation contains certain forward looking statements relating to the company's business prospects and the development and commercialization of pelareorep, a first-in-class systemically administered immuno-oncology agent for solid tumors and heme malignancies. These statements are based on management's current ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F | o | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 | | --- | --- | | | OR | | x | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | | | For fiscal year ended | | | December 31, 2018 | | | OR | | o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | For the transition period from ____ to ____ OR o SHEL ...

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2018 Results Earnings Conference Call March 8, 2019 8:30 AM ET Company Participants Michael Moore - VP of IR & Corporate Communications Matthew Coffey - President, CEO Kirk Look - CFO Conference Call Participants Wangzhi Li - Ladenburg Thalmann Operator Good morning. My name is Michelle, and I will be your conference operator today. At this time, I would like to welcome everyone to the Oncolytics Biotech Fourth Quarter Results Conference Call. All lines have been pla ...